Streetbeat News

Stock Prices

ARCT

Arcturus Therapeutics and CSL have announced that their self-amplifying mRNA COVID-19 vaccine showed a superior immune response compared to a standard mRNA vaccine 12 months after vaccination.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:02 pm

CVS

CVS shares are experiencing an uptick as Glenview Capital Management engages with company executives to discuss potential operational improvements.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:01 pm

BLFS

In the past three months, four analysts have rated BioLife Solutions (NASDAQ:BLFS), with a majority being bullish. The average 12-month price target has increased by 22.83% to $28.25. Despite positive analyst sentiment, BioLife faces financial challenges, including a decline in revenue and below-average profitability metrics.

Portfolio Pulse from Benzinga Insights

September 30, 2024 | 12:01 pm

INMB

INmune Bio Inc. has completed enrollment for its Phase 2 trial targeting early Alzheimer's disease, marking a significant milestone in its clinical development process.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:01 pm

ALIT

In the past three months, six analysts have provided ratings for Alight (NYSE:ALIT), with a mix of bullish and neutral perspectives. The average 12-month price target has decreased by 13.64% to $9.5. Alight faces challenges with a 4.1% revenue decline, but maintains a strong net margin.

Portfolio Pulse from Benzinga Insights

September 30, 2024 | 12:01 pm

ELF

e.l.f. Beauty (NYSE:ELF) has received mixed analyst ratings over the past three months, with a majority being bullish. The average 12-month price target has decreased by 4.44% to $212.67. Despite a smaller market capitalization, e.l.f. Beauty has shown strong financial performance with a 49.99% revenue growth rate, a 14.66% net margin, and a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

September 30, 2024 | 12:00 pm

BL

In the past three months, 8 analysts have rated BlackLine (NASDAQ:BL), with a mix of bullish and bearish perspectives. The average 12-month price target is $59.88, down 6.26% from the previous average. Recent analyst actions include both upgrades and downgrades, reflecting varied expectations for BlackLine's performance. Despite strong financial metrics like a high net margin and ROE, BlackLine faces challenges with its high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

September 30, 2024 | 12:00 pm

ULCC

Analysts have provided mixed ratings for Frontier Group Holdings (NASDAQ:ULCC) over the past three months, with a notable decrease in the average 12-month price target. The company's financial performance shows challenges in profitability and asset utilization, despite a strong return on equity.

Portfolio Pulse from Benzinga Insights

September 30, 2024 | 12:00 pm

BABA

JD

NIO

PDD

US-listed Chinese companies' shares are rising due to strong stimulus efforts and better-than-expected September PMI data, despite a decline in factory activity.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 11:59 am

AIQ

AVEM

BABA

JD

NVDA

XPEV

Alibaba's stock is rising due to China's stimulus plans, including a cut in banks' reserve requirement ratio and reverse repurchase rate. Alibaba is expected to benefit from these measures, with its cloud services and international expansion enhancing its position. The company is collaborating with Nvidia on autonomous driving and has partnered with XPeng. Additionally, Alibaba and JD.com have integrated logistics and payment services to combat demand slowdown. Alibaba's stock has gained 20% in the last 5 days.

Portfolio Pulse from Anusuya Lahiri

September 30, 2024 | 11:54 am